US FDA approves NPS Pharma's Natpara

24 January 2015
2019_biotech_test_vial_discovery_big

The US Food and Drug Administration on Friday approved NPS Pharmaceuticals’ (Nasdaq: NPSP) Natpara (parathyroid hormone) to control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism, a rare disease that affects about 60,000 people in the USA.

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is expected to be available in the second quarter of 2015, said NPS Pharma.

NPS Pharma is the subject of a $5.2 billion ($46.00 per share) agreed takeover by Ireland-headquartered drugmaker Shire’s (LSE: SHP), and the approval of Natpara is seen as validation of the 50% premium that Shire has offered for the company. NPS Pharma’s shares edged up 0.68% to $45.95 in after-hours trading on January 23. Shire’s shares gained 2.2% to £48.16.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology